7:13 AM ET
8-K
Contract Win
Marker Therapeutics Wins $2.6M Contract from Food & Drug Administration
Marker Therapeutics was awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to advance its lead MAR-T cell therapy, MT-601, for pancreatic cancer. The non-dilutive funding will support a Phase 1 clinical study in patients with locally advanced unresectable pancreatic cancer. Marker was one of only six recipients selected from 66 applications in fiscal year 2026.
- Value
- $2.6M
- Counterparty
- Food & Drug Administration